NCT02310477 2026-03-13
REBECCA
Centre Oscar Lambret
Completed
Clinical Trials
70 trialsNCT02386397 2026-03-12
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT06071052 2026-03-05
DREAM
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Completed
NCT06137170 2026-03-02
RegoSeq
Bayer
Completed
NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT03712943 2026-02-09
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04362839 2026-01-28
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT04660812 2025-10-20
ARC-9
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT05064059 2025-09-17
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04874207 2025-08-08
RePERSO
Rennes University Hospital
Phase 4 Completed
NCT02368886 2025-06-18
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT04704154 2025-04-18
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
Phase 2 Completed
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT03627728 2025-03-13
a-MANTRA
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT06029010 2025-02-26
COLONGER
Bayer
Completed
NCT04534218 2024-12-20
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT03564938 2024-12-03
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
Bayer
Phase 4 Completed
NCT02175095 2024-10-04
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Asan Medical Center
Phase NA Completed
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT03890731 2024-04-02
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Phase 2 Completed
NCT02316340 2024-01-05
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02195011 2023-12-05
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02024607 2023-11-15
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03215264 2023-11-09
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02106858 2023-07-24
StivargaPMS
Bayer
Completed
NCT04126733 2023-07-18
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Bayer
Phase 2 Completed
NCT05942768 2023-07-12
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Hunan Cancer Hospital
Completed
NCT03289273 2023-06-13
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Bayer
Completed
NCT02638766 2023-03-27
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT04310709 2022-12-06
RENOBATE
Asan Medical Center
Phase 2 Completed
NCT02307500 2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2 Completed
NCT02080260 2022-04-21
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
Wake Forest University Health Sciences
Phase 2 Completed
NCT02115542 2021-10-12
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03829852 2021-07-23
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
Taipei Veterans General Hospital, Taiwan
Completed
NCT02164240 2021-06-14
SURE
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03305913 2021-03-26
REMETY
AIO-Studien-gGmbH
Phase 1 Completed
NCT01271712 2021-01-29
GRID
Bayer
Phase 3 Completed
NCT01298570 2021-01-06
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03081494 2020-12-11
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Novartis
Phase 1 Completed
NCT01068769 2020-08-24
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01913639 2020-05-15
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02835924 2020-03-10
RE-ARRANGE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT02889328 2020-01-09
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Asan Medical Center
Phase 2 Completed
NCT02788279 2019-12-11
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
Hoffmann-La Roche
Phase 3 Completed
NCT02406170 2019-10-22
REPEAT
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT02651415 2019-09-12
PARICCA
British Columbia Cancer Agency
Phase 2 Completed